Bristol-Myers Squibb (BMY) stock slipped on Tuesday despite news of an artificial intelligence (AI) agreement with tech giant Microsoft (MSFT). This deal will have Microsoft supply Bristol-Myers Squibb with its Precision Imaging Network to accelerate the detection of lung cancer. This platform utilizes AI to analyze X-ray and CT images to aid in the detection of lung disease.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alexandra Goncalves, Vice President and Head of Digital Health at Bristol-Myers Squibb, said, “By combining Microsoft’s highly scalable radiology solutions with Bristol’s deep expertise in oncology and drug delivery, we have envisioned a unique AI-enabled workflow that helps clinicians quickly and accurately identify patients with non-small cell lung cancer and guide them to optimal care pathways and precision therapies.”
The deal between Bristol-Myers Squibb and Microsoft highlights the growing demand for AI. The tech has undergone a massive boom over the past year, and it appears that demand won’t waver in 2026.
Bristol-Myers Squibb & Microsoft Stock Movements Today
Bristol-Myers Squibb stock was down 0.82% on Tuesday but was still up 2.8% year-to-date. However, the stock has fallen 3.12% over the past 12 months. Trading activity today had some 2.18 million shares traded, compared to a three-month daily average of about 13.67 million units.
Microsoft stock was down 1.28% on Tuesday and has fallen 6.24% year-to-date. Even so, the shares were still up 7.32% over the past 12 months. Trading activity today saw some 5.64 million shares change hands, compared to a three-month daily average of about 21.58 million units.
BMY vs. MSFT: Which Stock Do Analysts Prefer?
Turning to the TipRanks stock comparison tool, traders can see which of these two stocks analysts favor. Microsoft has the better analysts’ consensus rating at Strong Buy, compared to a Moderate Buy rating for Bristol-Myers Squibb. MSFT stock also has the higher upside potential at 38.74%, compared to a possible 2.74% for BMY stock.
